CClinicalTrials.gg
CompletedNCT05681793CADEPOUpdated Jun 22, 2023

Survey on the Clinical Assessment of the Psychological Status of a Patient Over 75 Years Old in Oncology During the Realization of the G8 Score (CADEPO)

An observational study in Depression, sponsored by Hopital Nord Franche-Comte. Completed at 1 site in France. Open to participants aged 75 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Hopital Nord Franche-Comte · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Ages
75 Years to 95 Years
Sex
All
01

Study summary

The goal of this observational study is to make a statement concerning the identification of depressive symptoms at the time of the realization of the G8 score in patients over 75 with cancer and followed in oncology.

The main question it aims to answer are:

  • Compare the medical hetero-evaluation of depressive symptoms via the G8 "neuro-psychiatric disorders" item score with a self-evaluation via the GDS-15 score
  • Evaluate the number of patients over 75 treated with antidepressants
  • Evaluate the proportion of patients with depressive symptoms according to the predisposing factors
  • Compare the number of patients followed in oncogeriatrics over the period from 01/01/2022 to 02/28/2022 and the period from 01/01/2023 to 02/28/2023

Participants will complete a self-questionnaire (GDS-15 score) as well as a socio-demographic sheet.

02

Conditions studied

  • Depression

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 200 is above the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Hopital Nord Franche-Comte is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients over 75 presenting eligibility criteria and undergoing oncological treatment and coming for consultation in the Hôpital Nord Franche-Comté

Inclusion criteria

  • Patients aged 75 and over
  • Patients receiving treatment at the day hospital or oncology week hospital
  • Patients informed and having not presented any opposition to their participation

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 75
  • Patients under guardianship or curatorship
  • Patients without social security
  • Cognitive disorders compromising the understanding of the information and the performance of the study (in particular the completion of a self-administered questionnaire), in the opinion of the oncologist
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Comparison the medical hetero-evaluation of depressive symptoms via the G8 "neuro-psychiatric disorders" item score with a self-evaluation via the GDS-15 score, in patients over 75 years of age with cancer and follow-up in oncology

    Difference between the evaluation of the health professionals of the item "Neuropsychiatric problems" of the G8 score (no depression versus moderate or severe depression) and the responses of the patients to the self-administered questionnaire GDS-15 (Geriatric Depression Scale) ( 0 to 4: normal versus 5 to 15: moderate to severe depression).

    Time frame: 2 months

Secondary outcomes

  1. Evaluation of the number of patients over 75 on antidepressants included in this study

    Percentage of patients included in this study and being treated with antidepressants

    Time frame: 2 months

  2. Evaluation of the proportion of patients with depressive symptoms according to the predisposing factors with a sociodemographic sheet and from the medical file

    Percentage of patients with depressive symptoms according to the predisposing factors (age, gender, housing in urban or rural areas,distance (in travel time) between the oncology department and home, social isolation, income, marital status, socio-professional category, type of cancer), taken from a sociodemographic sheet distributed to the patient and from the medical file

    Time frame: 2 months

  3. Compare the number of patients followed in oncogeriatrics over the period from 01/01/22 to 02/28/22 and the period from 01/01/2023 to 02/28/2023

    Percentage of patients followed in oncogeriatrics over the period from 01/01/2022 to 02/28/2022 and the period from 01/01/2023 to 02/28/2023

    Time frame: 2 months

07

Study locations

1 site
  • Hôpital Nord Franche-Comté
    Trévenans, 90400, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05681793
Lead sponsor
Hopital Nord Franche-Comte
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Jan 17, 2023
Primary completion
Mar 2, 2023
Completion
Apr 2, 2023
Last update
Jun 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion